Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis

What Was Tested

This clinical trial, phase i paper looks at Survodutide and Glucagon.

Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH).

Who Took Part

According to the abstract, 3 people were involved.

PubMed indexes the participants as adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as open-label.

Nothing was hidden in this open-label Survodutide study: the people and staff both knew the treatment.

The methods mention a period of 24 weeks.

What Was Measured

Topics PubMed links to this paper include Liver Cirrhosis, Glucagon, Obesity and Glucagon-Like Peptide-1 Receptor Agonists.

Author keywords: metabolic diseases and non-alcoholic fatty liver disease.

What This Means in Plain Language

The paper is an open-label study of Survodutide and Glucagon in 3 people over 24 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Journal of hepatology), a journal based in Netherlands.

More context: the Survodutide compound page and the Glucagon compound page, all human trials.